Protocol Ledger

NCT04294810 · Phase III · COMPLETED

A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Ce

Interventional Phase III clinical trial protocol NCT04294810 sponsored by Roche / Genentech in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-03-04 Enrollment: 620 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04294810
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)620 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04294810
Protocol FieldVerified Registry Value
NCT IdentifierNCT04294810
Consolidated Lead SponsorRoche / Genentech
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment620 participants (ACTUAL)
Registered Start Date2020-03-04
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04294810
Hospital Research SiteLocationSite Profile
Yale Cancer Center and Smilow Cancer HospitalNew Haven, CTOpen Hospital Dossier ->
Florida Cancer Specialists (Saint Petersburg)Saint Petersburg, FLOpen Hospital Dossier ->
SCRI Oncology PartnersNashville, TNOpen Hospital Dossier ->
Princess Alexandra HospitalWoolloongabba, AustraliaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI